Our top stories

April 27, 2021

Exscientia announces investment of up to $525M

Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities. $225 million Series D round closed with access up to an additional $300 million at Exscientia’s discretion. Financing led by SoftBank Vision Fund 2.

What Comes Next Podcast - Special Episode

Listen

Tech vs. The Coronavirus

World Summit of AI 2019

January 15, 2021

AACR

We attended Session PO.IM02.07 and presented EXS21546, our non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy (Poster 1731)

Exscientia awards

Nothing yet